Erratum: Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma (New England Journal of Medicine (2018) 378 (331-344) DOI: 10.1056/NEJMoa1708984);Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma

New England Journal of Medicine

Volumn 378, Issue 4, 2018, Pages 331-344

  Connors, J M ^a   Jurczak, W ^b   Straus, D J ^g   Ansell, S M ^h   Kim, W S ⁱ   Gallamini, A ^j   Younes, A ^g   Alekseev, S ^k   Illes A ^l   Picardi, M ⁿ   Lech Maranda, E ^c,d   Oki, Y ^p   Feldman, T ^q   Smolewski, P ^e   Savage, K J ^a   Bartlett, N L ^r   Walewski, J ^f   Chen, R ^s   Ramchandren, R ^t   Zinzani, P L ^o   Cunningham, D ^u   Rosta, A ^m   Josephson, N C ^w   Song, E ^w   Sachs, J ^x   Liu, R ^x   Jolin, H A ^x   Huebner, D ^x   Radford, J ^v   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h MAYO CLINIC   (United States)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j CENTRE ANTOINE LACASSAGNE   (France)

^k N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^l UNIVERSITY OF DEBRECEN   (Hungary)

^m NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁿ FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^q HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^r WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^t KARMANOS CANCER INSTITUTE   (United States)

^u INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^v UNIVERSITY OF MANCHESTER   (United Kingdom)

^w SEATTLE GENETICS INC   (United States)

^x MILLENNIUM PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; DACARBAZINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; INFECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; TREATMENT OUTCOME; VOMITING; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL RATE; VINBLASTINE; YOUNG ADULT;

EID: 85041389324     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMx180007     Document Type: Erratum

References (27)

1. Engert A. ABVD or BEACOPP for advanced Hodgkin lymphoma. J Clin Oncol 2016; 34: 1167-9.
2. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
3. Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial. J Clin Oncol 2016; 34: 2028-36.
4. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advancedstage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013; 31: 684-91.
5. Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004; 22: 1532-3.
6. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 23: 7614-20.
7. Borchmann P, Goergen H, Kobe C, et al. Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim PET: final results of the international, randomized phase 3 trial HD18 by the German Hodgkin Study Group. Haematologica 2017; 102: S150. abstract.
8. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 2016; 374: 2419-29.
9. Borchmann P, Eichenauer DA, Pluetschow A, et al. Targeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: final analysis of a randomized phase II study. Blood 2015; 126: 580. abstract.
10. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65-7.
11. Adcetris (brentuximab vedotin). Bothell, WA: Seattle Genetics, 2016 (package insert) (http://www.seattlegenetics.com/application/files/2515/1059/6728/ADCETRIS-USPI-USP-BVP-2015-01625pdf.pdf).
12. Adcetris (brentuximab vedotin). EU summary of product characteristics (http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002455/WC500135055.pdf).
13. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013; 14: 1348-56.
14. Connors JM, Ansell SM, Fanale M, Park SI, Younes A. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. Blood 2017; 130: 1375-7.
15. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14.
16. Meignan M, Gallamini A, Haioun C, Polliack A. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010; 51: 2171-80.
17. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol1989; 7: 1630-6.
18. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-32.
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
20. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
21. Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol 2011; 22: 910-5.
22. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PETguided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-9.
23. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after firstline treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-8.
24. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052-60
25. Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol 2011; 2011: 725219.
26. Matasar MJ, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. J Natl Cancer Inst 2015; 107(4): djv018.
27. Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol 2016; 53: 209-15.